Opko Health Inc (OPK)

[Femto99]

Rare Disease IDM Director Somatrogon
United Kingdom - Walton Oaks
Europe - Any Pfizer Site
Europe - Remote

Pfizer has a long legacy in Growth Hormone space having launched Genotropin in 1986. Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in approximately 4,000 to 10,000 people. Somatrogon (Long Acting Growth Hormone) represents significant innovation and has the potential to provide an important treatment advance over the current standard of care for growth hormone deficiency, which requires once-daily injection. If approved, somatrogon could reduce the daily disease burden on children and their caregivers, potentially increasing treatment adherence. While the medicine has been developed in partnership with OPKO health, global commercialization is solely a Pfizer responsibility.

Global Marketing

Manage launch execution and readiness plan for IDM markets, working in partnership with the overall global brand launch execution lead

Develop IDM pricing and market access strategy in partnership with the PHI

Lead global competitive intelligence efforts for Growth Hormone, and translate IDM market specific insights to the region

Support overall Growth Hormone franchise strategy, including device strategy and co-positioning of Somatrogon and Genotropin, via the incorporation of deep IDM insights

Support IDM market specific pull-through of the branding, positioning and core campaign for the launch for Somatrogon

https://pfizer.wd1.myworkdayjobs.com/en-US/InternalJobs/job/United-Kingdom---Walton-Oaks/Rare-Disease-IDM-Director-Somatrogon_4792302